Firategrast

Firategrast is an orally bioavailable α4β1/α4β7 integrin antagonist.

Signaling Pathways >> Cytoskeleton >> Integrin

Research Areas >> Neurological Disease

α4β1/α4β7[1]

Firategrast is an orally bioavailable α4β1/α4β7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS)[1].

[1]. Grove RA, et al. Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis. Eur J Neurol. 2013 Jul;20(7):1032-42.

Cilengitide | Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate salt | Arg-Gly-Asp-Ser | CWHM-12 | OSU-T315 | E 7820 | GLPG 0187 | ATN-161 trifluoroacetate salt | Cucurbitacin B | Eptifibatide acetate salt | iRGD peptide | Lifitegrast | Zaurategrast | Integrin Antagonist 1 (hydrochloride) | TR 14035